Kura Oncology (KURA) Expected to Release Earnings on Tuesday

Kura Oncology (NASDAQ:KURA) is expected to post its Q3 2026 results after the market closes on Tuesday, November 3rd. Analysts expect Kura Oncology to announce earnings of ($0.8144) per share and revenue of $24.86 million for the quarter. Individuals can find conference call details on the company’s upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Tuesday, November 3, 2026 at 8:00 AM ET.

Kura Oncology (NASDAQ:KURA) last posted its earnings results on Wednesday, August 12th. The company reported ($0.77) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.88) by $0.11. The firm had revenue of $20.87 million during the quarter, compared to analysts’ expectations of $20.16 million. Kura Oncology had a negative net margin of 384.30% and a negative return on equity of 207.18%. On average, analysts expect Kura Oncology to post ($3.25) EPS for the current fiscal year and ($2.46) EPS for the next fiscal year.

Kura Oncology Stock Up 0.1%

Kura Oncology stock opened at $9.62 on Tuesday. Kura Oncology has a 1-year low of $7.36 and a 1-year high of $13.90. The firm’s fifty day simple moving average is $11.28 and its 200-day simple moving average is $9.79. The company has a market capitalization of $855.80 million, a P/E ratio of -2.85 and a beta of 0.47. The company has a current ratio of 4.73, a quick ratio of 4.71 and a debt-to-equity ratio of 0.12.

Insider Transactions at Kura Oncology

In other Kura Oncology news, insider Francis Burrows sold 20,726 shares of the firm’s stock in a transaction dated Thursday, September 24th. The stock was sold at an average price of $10.83, for a total transaction of $224,462.58. Following the transaction, the insider owned 42,327 shares in the company, valued at approximately $458,401.41. This trade represents a 32.87% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Troy Wilson acquired 100,000 shares of Kura Oncology stock in a transaction that occurred on Monday, August 17th. The shares were purchased at an average cost of $11.12 per share, for a total transaction of $1,112,000.00. Following the purchase, the chief executive officer directly owned 379,194 shares in the company, valued at $4,216,637.28. The trade was a 35.82% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. In the last quarter, insiders sold 153,881 shares of company stock valued at $1,708,183. 7.60% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

Several equities research analysts recently weighed in on KURA shares. Raymond James Financial set a $24.00 target price on Kura Oncology in a report on Monday, August 24th. Wedbush upped their price target on Kura Oncology from $36.00 to $38.00 and gave the company an “outperform” rating in a report on Thursday, August 13th. Deutsche Bank Aktiengesellschaft set a $24.00 target price on shares of Kura Oncology in a research note on Wednesday, October 14th. JPMorgan Chase & Co. began coverage on Kura Oncology in a research note on Thursday, October 1st. They set an “overweight” rating and a $30.00 price objective for the company. Finally, Barclays set a $24.00 price objective on shares of Kura Oncology in a report on Wednesday, October 14th. Eleven research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Kura Oncology currently has an average rating of “Moderate Buy” and an average price target of $25.35.

Kura Oncology Company Profile

Kura Oncology, Inc (NASDAQ: KURA) is a biopharmaceutical company focused on developing precision medicines for the treatment of cancer. The company’s research programs target genetic and molecular drivers of malignancies, with the goal of developing therapies for patients with limited treatment options.

Kura’s lead product candidate has been ziftomenib, an oral, selective menin inhibitor being developed for genetically defined forms of acute myeloid leukemia (AML), including AML associated with NPM1 mutations and KMT2A rearrangements.